Company:  HYPERION THERAPEUTICS INC (HPTX)
Form Type:  10-Q
Filing Date:  5/10/2013 
CIK:  0001386858 
Address:  2000 SIERRA POINT PARKWAY
SUITE 400
 
City, State, Zip:  BRISBANE, California 94005 
Telephone:  650-745-7802 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$25.53  
Change: 
-0.08 (-0.31%)  
Trade Time: 
Apr 24  
Market Cap: 
$517.34M
Description of Business
We are a commercial biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Our products, RAVICTI� (glycerol phenylbutyrate) Oral liquid, BUPHENYL� and AMMONAPS� (sodium phenylbutyrate) Tablets and Powder, are designed to lower ammonia in the blood. Ammonia is produced in the intestine after a person eats protein and is normally detoxified in the liver by conversion to urea. Elevated levels of ammonia are potentially toxic and can lead to severe medical complications which may include death. We have developed RAVICTI, which we launched during the first quarter of 2013, to treat most urea cycle disorders (�UCD�) including 7 of the 8 most prevalent UCD subtypes, and are developing glycerol phenylbutyrate (�GPB�), the active pharmaceutical ingredient in RAVICTI, to treat hepatic encephalopathy (�HE�). UCD and HE are diseases in which blood ammonia is elevated.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      Item 1. Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        Notes to Condensed Consolidated Financial Statements (Unaudited)
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures
    PART II. OTHER INFORMATION
      Item 1. Legal Proceedings
      Item 1A. Risk Factors
      Item 2. Unregistered Sales of Equity Securities and Use of ...
      Item 3. Defaults Upon Senior Securities
      Item 4. Mine Safety Disclosures
      Item 5. Other Information
      Item 6. Exhibits
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 31.1
    CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
  EXHIBIT 31.2
    CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO
BROKERAGE PARTNERS